Zheng Quan Zhi Xing·2025-07-14 11:17Core Viewpoint - The company, Beijing Beilu Pharmaceutical Co., Ltd., is proceeding with the early redemption of its convertible bonds, "Beilu Convertible Bonds," following the necessary approvals and compliance with relevant regulations [1][7]. Group 1: Convertible Bond Basic Information - The total issuance amount of the convertible bonds is 500 million yuan, approved by the China Securities Regulatory Commission [1]. - The bonds were listed on the Shenzhen Stock Exchange on December 28, 2020, under the name "Beilu Convertible Bonds" with the code "123082" [1]. - The conversion period for the bonds starts six months after issuance and lasts until the maturity date [1]. Group 2: Conversion Price Adjustment - The initial conversion price was set at 11.41 yuan per share, which was adjusted down to 8.86 yuan per share on February 8, 2021, due to stock price conditions [2]. - Further adjustments were made to the conversion price, with the latest adjustment bringing it down to 7.02 yuan per share effective from May 19, 2025 [5]. Group 3: Conditional Redemption Terms - The bonds have a conditional redemption clause that allows the company to redeem them if the stock price reaches 130% of the conversion price [6]. - The stock price condition for redemption was met between June 17, 2025, and July 14, 2025, triggering the company's right to redeem the bonds [6]. Group 4: Decision-Making Process for Redemption - The company's board of directors approved the early redemption of the bonds to optimize capital structure and reduce financial costs [6]. - The management was authorized to handle all matters related to the redemption process [6]. Group 5: Compliance and Verification - The underwriting institution, CITIC Construction Investment Securities, confirmed that the early redemption process complies with relevant regulations and internal approvals [7].